Work

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

Year: 2016
Type: review
Abstract: More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,990
OpenAlex ID: W2296618733
FWCI: 4.183
Cites: 40
Cited by: 274
Related to: 10